Michael Torres focuses on innovation at the intersection of technology, medicine, and healthcare delivery. His coverage spans medical devices, digital health, diagnostics, and emerging care models. At The Catalyst Brief, Michael evaluates how new tools translate from concept to real-world impact, considering clinical evidence, adoption challenges, and broader industry implications.
129 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biotech InnovationGLP-1 receptor agonists have revolutionized treatment for obesity and diabetes. Emerging evidence shows that genetics might have a subtle impact on how individual patients experience efficacy and side effects from these drugs. Understanding these nuances could refine personalized medicine approaches in biotech.
Michael TorresApr 9, 2026
Biopharmaceutical IndustryThe strategic purchase marks a significant investment by Gilead into cancer therapeutics by incorporating Tubulis' cutting-edge ADC technology. This expansion will boost Gilead's presence in the oncology space, addressing critical needs in cancer therapy.
Michael TorresApr 7, 2026
Regulatory & PolicyWith a focus on accelerating pharmaceutical innovation and enhancing public health, the FDA plans to make rare disease vouchers a permanent program and facilitate easier clinical entry for new therapeutics. These changes aim to support faster development pathways for treatments addressing rare and complex conditions.
Michael TorresApr 7, 2026
Medical TechnologyAs artificial intelligence increasingly transforms medical devices, the FDA is adapting its regulatory framework to address the nuances of AI-powered technologies. This post explores recent trends in breakthrough device approvals, how the agency balances innovation and safety, and what this means for the future of medical technology.
Michael TorresApr 2, 2026
Regulatory & PolicyObesity diagnosis is at a crossroads with a proposed new definition aiming to refine the clinical identification of the condition before it fully manifests. This initiative has sparked a global debate involving endocrinologists, healthcare professionals, and policy makers, with proponents and critics weighing the implications for patient care and healthcare disparities.
Michael TorresApr 2, 2026
Regulatory & PolicyEli Lilly’s recent FDA approval for its oral obesity drug, orforglipron, branded as Foundayo, introduces a potent new player in the obesity treatment market. This milestone triggers a strategic rivalry with Novo Nordisk, whose oral Wegovy has dominated the segment. This analysis explores the implications of this approval, expected market dynamics, and how this competition might shape the future of obesity therapeutics.
Michael TorresApr 1, 2026
AI in Drug DiscoveryThe infusion of $17 million from investors including M13 and Town Hall Ventures will enable Jimini Health to scale its AI platform Sage, which integrates clinician supervision to provide complex mental health care. This development marks a significant step in AI-driven behavioral health solutions.
Michael TorresApr 1, 2026
Biopharmaceutical IndustryBy acquiring Centessa Pharmaceuticals, Eli Lilly gains access to cleminorexton, an orexin agonist drug candidate that may revolutionize treatment for narcolepsy and other sleep disorders. This move aligns Lilly with other leading pharmaceutical companies developing innovative therapies in sleep science.
Michael TorresApr 1, 2026
Medical TechnologyThe collaboration aims to broaden the reach of gut microbiome testing, offering greater accessibility and personalization for consumers interested in understanding their gut health. This partnership reflects a growing trend toward incorporating microbiome data into consumer health monitoring and wellness strategies.
Michael TorresMar 30, 2026
Healthcare InvestmentThe assessment of return on investment (ROI) for AI initiatives within health systems is undergoing a significant transformation. As budgetary pressures intensify, leaders are adopting expanded frameworks that value not only direct cost savings but also indirect benefits like improved clinician well-being and operational efficiencies, marking a paradigm shift in how these technologies are integrated.
Michael TorresMar 29, 2026
AI in Drug DiscoveryHealth systems are increasingly leveraging AI technologies that predict risks with growing accuracy. However, meaningful improvements in preventive care delivery require combining these insights with deliberate human outreach and healthcare planning. This synergy is central to harnessing AI’s full potential to expand access.
Michael TorresMar 29, 2026
Biotech InnovationWith its cutting-edge approach inspired by advances in cancer therapy, Alumis is making strides in the treatment of autoimmune disorders. Phase 3 clinical trial results for envudeucitinib are highly anticipated and set to be presented at the American Academy of Dermatology annual meeting.
Michael TorresMar 28, 2026